A new phase 1 trial demonstrates the safety and effectiveness of personalized neoantigen DNA vaccines, showing promising ...

Our study found that doing these kinds of screenings on patients doesn't make any marked difference in their long-term survival rates." J. Brent Muhlestein, principal investigator of the study and ...

LONDON, UK I 14, 2024 I GSK plc (LSE/NYSE: GSK) today announced positive headline results from a planned interim analysis of the DREAMM-7 ...

A recent study from the University of Würzburg unveiled a key enzyme involved in producing selenoproteins, opening new ...

Discover reliable and free data sources to enhance your SEO content strategy. Build authority and credibility with accurate and trustworthy data. The internet is awash in an endless stream of ...

Here's why it made the list ...

These are independent reviews of the products mentioned, but TIME receives a commission when purchases are made through ...

Reducing the risk of metastatic relapse in patients with resectable soft tissue sarcomas is crucial for improving outcomes, because metastasis is the primary cause of mortality in this population.

The treatment landscape for patients with prostate cancer, especially individuals with advanced disease, has dramatically changed in recent years.

Mass spectrometry and machine learning show promise for early cancer detection and prognosis by analyzing metabolic ...

Oncology trials often celebrate treatments improving progression-free survival, yet toxicity-related censoring can bias ...